DXS Track Two

Date: Thursday, 13 October 2016 - Friday, 14 October 2016
Location: Singapore

Guest of Honour

Lim Chuan Poh
Chairman, A*STAR

Plenary Speakers

Steven Myint
Senior fellow, Consultant, Adjunct Professor, Chairman, ETPL, Duke-NUS, Inex Private Ltd

Chwee Teck Lim
NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute, National University of Singapore

Rudi Pauwels
Founder Director/Chief Executive Officer, Biocartis

Jean-Luc Butel
Global Healthcare Advisor, President, K8 Global & Senior Advisor , McKinsey&Company

Fred Kramer
Professor, New Jersey Medical School Rutgers University

Keynote Speakers

David Wong
Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles

John CW Lim
Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School Singapore, Deputy Director of Medical Services (Industry & Research Matters) , Ministry of Health

Roger Foo
Group Leader, GIS

Patrick Tan
Professor, Duke-NUS Medical School and Deputy Executive Director, Biomedical Research Council, A*STAR

Mahesh Choolani
Research Director , National University Health System (NUHS)

Overview

Select Bio and the Diagnostics Development Hub, part of Exploit Technologies Pte. Ltd. present Singapore’s inaugural Diagnostics Summit.

The event will take place on the 13-14 October at the Biopolis, Singapore’s custom built biomedical research and development hub, home to a large number of the world’s leading Life Science organisations and A*STAR research institutes.

Bringing together industry professionals, entrepreneurs, researchers, academia and students, this comprehensive two day meeting will look to address the challenges of translating the latest advances in scientific research into tangible diagnostics solutions.

A key focus for this conference track is to discuss the relative attributes of both Circulating Biomarkers and Tissue-Based Biomarkers for Companion Diagnostics. We will also highlight Emerging Technologies and Services within the Liquid Biopsy space, in addition to discussing Technology Commercialization, the Regulatory Landscape and Market Entry into Asia.

Please see below for a comprehensive list of the subject areas to be addressed.

Session Sponsors

Agenda Topics

Circulating Biomarkers vs. Tissue-based Biomarkers for Companion Diagnostics Development

Companion Diagnostics in Various Disease Classes
Epigenetic Modifications (Hypermethylation of specific genes) as Biomarkers for Diagnostics
Next-Generation Sequencing (NGS) for Liquid Biopsy Development and Companion Diagnostics
Protein Biomarkers versus Nucleic Acid Biomarkers for Companion Diagnostics Development
Therapeutic Potential: Automimmune Diseases, Cancer, Cardiovascular Disease, CNS and Neurodenerative Diseases and Traumatic Brain Injury, Pregnancy and Reproductive Health

Technology & Company Showcase, Commercialization & the Regulatory Landscape

Asia/Pacific vs EU vs US Regulatory Landscape and Barriers to Entry
Company Case Studies
Emerging Technology Showcase: Companies Highlight Products and Services in the Liquid Biopsy Space
Transforming your IPs into clinically validated Diagnostic Devices
Why Singapore?

Sponsorship and Exhibition Opportunities

Paul Raggett, Exhibition Manager
p.raggett@selectbio.com
+855 6999 5137

Confirmed Speakers to date

Angela Barrett, Research Fellow, National University of Singapore
Olli Carpen , Professor of Pathology, Scientific Director , University of Helsinki & Helsinki Biobank
Jeff Chen, Sales Director of SE Asia and Korea, BioDot Inc
Takahiro Inatsugi, Assistant Director, Specialty Chemicals Division, Nicca Chemical Co.,Ltd.
Winston Koh, Scientist, Stanford University
Say Li Kong, Research Associate, Genome Institute of Singapore
Johnson Ng, Founder And CEO, JN Medsys Pte Ltd
Sarah Ng, Post-doctoral Fellow , IMCB
Siew Hwa Ong, CEO, Acumen Research Laboratories
Richie Soong, Senior Principle Investigator, National University of Singapore
Min-Han Tan, Team Leader, Principal Research Scientist, Institute Of Bioengineering & Nanotechnology A*Star
Hwee Ee Tan, Principal Consultant/Director, DH RegSys Pte Ltd
Jinkai Teo, Scientist, Merck
Nat Whitney, President, Whitney Research, Inc
Lihan Zhou, Co Founder/Chief Technology Officer, MiRXES Pte Ltd